Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
[116 Pages Report] The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period. Growth in this market is driven by the rising global prevalence of hematologic cancer, growing awareness regarding personalized medicines, and increasing collaborations for developing new assays. On the other hand, Uncertain reimbursement scenario in different regions is expected to restrain the growth of this market during the forecast period.
“The services segment accounted for the largest share of the hemato oncology testing in 2018”
Based on product & services, the hemato oncology testing is segmented into services and assay kits. In 2018, the services segment accounted for the largest share of the hemato oncology testing. This is mainly due to the increasing prevalence & incidence of leukemia, non-Hodgkin lymphoma, and myeloma cancers. Apart from this, rising awareness regarding advanced treatment therapies such as personalized medicine is also driving the growth of this segment.
“NGS segment is expected to grow at the highest growth rate during the forecast period”
Based on the technology, the market has been segmented further into five subsegments, viz., PCR, IHC, NGS, cytogenetics, and other technologies. Among these, the PCR segment is estimated to dominate the market in 2019, due to the extensive use of this technology owing to its ease of use and easy availability of assay kits. However, NGS is expected to grow at the highest growth rate in the coming years due to its advantages, such as more specificity and sensitivity.
“Asia Pacific to register the highest growth rate during the forecast period (2019–2024)”
Based on region, the hemato oncology testing is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). While North America dominated the market in 2018, Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC market is driven mainly by the large patient population, and increasing focus of major players on expanding in this region will drive market growth.
Key Market Players
Prominent players in the hemato oncology testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).
F. Hoffmann-La Roche Ltd. (Switzerland) was the leading player in the market in 2018. The company offers a full range of tests for the diagnosis of hemato-oncology cancers, such as leukemia, lymphoma, and myeloma, among others. Its active presence across the globe, robust distribution channels, and brand image help the company to maintain a dominant position in the market. Roche has been focusing on emerging markets, the Asia Pacific, in particular, to increase its presence and revenues. Asia Pacific contributed to 26% of the total sales of the company in 2018. The company has also been investing 11-13% of its total revenue for R&D activities since the past three years.
Abbott Laboratories (US) was the second-largest player in the market in 2018. Over the last few years, the company has been investing approximately 6-9% of its total revenue on R&D. As a result, the company has been able to introduce products, such as Abbott RealTime IDH1 and Abbott RealTime IDH2 assay kits, into the market.
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for Years |
2017–2024 |
|
Base Year Considered |
2018 |
|
Forecast Period |
2019–2024 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product & Service, Cancer Type, Technology, End User, and Region |
|
Geographies Covered |
North America (the US and Canada), Europe, APAC, and the RoW |
|
Companies Covered |
Major 10 players covered, including: |
This research report categorizes the hemato oncology testing market into the following segments and subsegments:
Hemato oncology testing Market, by Product & Service
- Services
- Assay Kits
Hemato oncology testing Market, by Cancer Type
- Leukemia
- Acute myeloid leukemia
- Acute lymphocytic leukemia
- Other leukemia (Chronic lymphocytic leukemia, chronic myeloid leukemia)
- lymphoma
- non-Hodgkin’s Lymphoma
- Hodgkin’s Lymphoma
- Other cancers (Myeloma, Myelofibrosis (MF), Essential Thrombocythemia)
emato oncology testing Market, by Technology
- PCR
- IHC
- NGS
- Cytogenetics
- Others
Hemato oncology testing Market, by End User
- Clinical laboratories
- Hospitals
- Academic & Research Institutes
- Other End Users (CROs, Pharmaceutical & Biotechnology Companies)
Hemato oncology testing Market, by Region
- North America
- US
- Canada
- Europe
- Asia Pacific
- Rest of the World
Recent Developments:
- In May 2018, Adaptive Biotechnologies (US) collaborated with Sanofi, SA. (US), to utilize Adaptive’s clonoSEQ Assay to measure MRD status in response to isatuximab
- In July 2018, Abbott Laboratories (US) received FDA approval for its Abbott RealTime IDH1 kit
- In May 2018, Invivoscribe, Inc. (US) partnered with the American University of Beirut Medical Center (AUBMC) (Lebanon) to create a new center of excellence facility in the Middle East
Key Questions Addressed in the Report:
- What are the growth opportunities in the hemato oncology testing across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of hemato oncology testing. Will this scenario continue during the next five years?
- What are the new trends and advancements in the hemato oncology testing?
- What initiatives are being undertaken by market players?
- Which of the segments will drive the market growth in the future?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 23)
4 Premium Insights (Page No. - 27)
4.1 Hemato-Oncology Testing: Market Overview
4.2 North America: Market, By Product and Service (2018)
4.3 Geographical Snapshot of the Hemato Oncology Testing Market
5 Market Overview (Page No. - 30)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Hematologic Cancer
5.2.1.2 Increasing Collaborations
5.2.1.3 Increasing Conferences on Personalized Medicine
5.2.2 Opportunities
5.2.2.1 Drug Diagnostics Co-Development
5.2.2.2 Emerging Markets
5.2.3 Restraints
5.2.3.1 Uncertain Reimbursement Scenario in Different Regions
5.2.3.2 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
5.2.4 Challenges
5.2.4.1 Intellectual Property Rights Protection Issues
6 Hemato Oncology Testing Market, By Product & Service (Page No. - 37)
6.1 Introduction
6.2 Services
6.2.1 Rising Incidence of Hematologic Cancer to Increase the Demand for Hemato-Oncology Services
6.3 Assay Kits
6.3.1 Growing Focus on the Development of Advanced Assay Kits to Drive the Growth of This Market Segment
7 Hemato Oncology Testing Market, By Cancer Type (Page No. - 42)
7.1 Introduction
7.2 Leukemia
7.2.1 Acute Myeloid Leukemia
7.2.1.1 Aml is the Most Common Acute Leukemia Affecting Adults
7.2.2 Acute Lymphocytic Leukemia
7.2.2.1 North America Accounted for the Largest Share of the All Segment
7.2.3 Other Leukemias
7.3 Lymphoma
7.3.1 Non-Hodgkin Lymphoma
7.3.1.1 Non-Hodgkin Lymphoma Holds the Largest Share of the Market for Lymphoma
7.3.2 Hodgkin Lymphoma
7.3.2.1 APAC Market for Hodgkin Lymphoma Will Grow at the Highest Rate
7.4 Other Cancers
8 Hemato Oncology Testing Market, By Technology (Page No. - 50)
8.1 Introduction
8.2 PCR
8.2.1 PCR Accounted for the Largest Share of the Market in 2018
8.3 IHC
8.3.1 IHC Accounted for the Second-Largest Share of the Market
8.4 NGS
8.4.1 NGS is Expected to Register the Highest Growth During the Forecast Period
8.5 Cytogenetics
8.5.1 North America Accounted for the Largest Share of the Cytogenetics Market
8.6 Other Technologies
9 Hemato Oncology Testing Market, By End User (Page No. - 56)
9.1 Introduction
9.2 Clinical Laboratories
9.2.1 Presence of Robust Infrastructure is the Major Driving Factor for This Segment
9.3 Hospitals
9.3.1 Hospitals Accounted for the Second-Largest Share of the Market, By End User
9.4 Academic & Research Institutes
9.4.1 APAC Market for Academic & Research Institutes Will Grow at the Highest Rate
9.5 Other End Users
10 Hemato Oncology Testing Market, By Region (Page No. - 62)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 The US Dominates the North American Market
10.2.2 Canada
10.2.2.1 Initiatives Undertaken By Healthcare Authorities in the Country to Ensure the Delivery of Better Public Healthcare to Support the Growth of the Market in Canada
10.3 Europe
10.3.1 Rising Focus on Biomarker Development in EU Countries to Support Market Growth
10.4 Asia Pacific
10.4.1 Asia Pacific Market to Witness the Highest Growth During the Forecast Period
10.5 Rest of the World
11 Competitive Landscape (Page No. - 84)
11.1 Overview
11.2 Market Ranking Analysis, 2017
11.3 Key Strategies
11.3.1 Product Launches & Approvals, 2016–2019
11.3.2 Expansions, 2016–2019
11.3.3 Partnerships and Collaborations, 2016–2019
11.3.4 Acquisitions, 2016–2019
12 Company Profiles (Page No. - 88)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 F. Hoffman-La Roche Ltd.
12.2 Abbott Laboratories
12.3 Qiagen N.V.
12.4 Thermo Fisher Scientific, Inc.
12.5 Illumina, Inc.
12.6 Bio-Rad Laboratories, Inc.
12.7 Molecularmd (Subsidiary of Icon PLC)
12.8 Archerdx, Inc.
12.9 Arup Laboratories Inc.
12.10 Asuragen, Inc.
12.11 Invivoscribe, Inc.
12.12 Adaptive Biotechnologies.
*Details on Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 109)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details
List of Tables (77 Tables)
Table 1 Hematologic Cancer Incidence, By Type, 2018–2040
Table 2 Geriatric Population, By Region, 2015 vs 2030
Table 3 Health Expenditure Per Capita, By Country, 2009 vs 2016
Table 4 Incidence of Hematologic Cancers, By Country, 2018 vs 2030
Table 5 Reimbursement Scenario for Hemato-Oncology Testing Products Across Regions
Table 6 Market, By Product & Service, 2017–2024 (USD Million)
Table 7 Hemato-Oncology Testing Services Market, By Region, 2017–2024 (USD Million)
Table 8 Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 9 Hemato-Oncology Testing Assay Kits Market, By Region, 2017–2024 (USD Million)
Table 10 Market, By Cancer Type, 2017–2024 (USD Million)
Table 11 Hemato Oncology Testing Market for Leukemia, By Region, 2017–2024 (USD Million)
Table 12 Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 13 Market for Acute Myeloid Leukemia, By Region, 2017–2024 (USD Million)
Table 14 Market for Acute Lymphocytic Leukemia, By Region, 2017–2024 (USD Million)
Table 15 Market for Other Leukemias, By Region, 2017–2024 (USD Million)
Table 16 Market for Lymphoma, By Region, 2017–2024 (USD Million)
Table 17 Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 18 Market for Non-Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 19 Hemato Oncology Testing Market for Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 20 Market for Other Cancers, By Region, 2017–2024 (USD Million)
Table 21 Market, By Technology, 2017–2024 (USD Million)
Table 22 Market for PCR, By Region, 2017–2024 (USD Million)
Table 23 Market for IHC, By Region, 2017–2024 (USD Million)
Table 24 Market for NGS, By Region, 2017–2024 (USD Million)
Table 25 Market for Cytogenetics, By Region, 2017–2024 (USD Million)
Table 26 Hemato Oncology Testing Market for Other Technologies, By Region, 2017–2024 (USD Million)
Table 27 Market, By End User, 2017–2024 (USD Million)
Table 28 Market for Reference Laboratories, By Region, 2017–2024 (USD Million)
Table 29 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 30 Market for Academic & Research Institutes, By Region, 2017–2024 (USD Million)
Table 31 Market for Other End Users, By Region, 2017–2024 (USD Million)
Table 32 Market, By Region, 2017–2024 (USD Million)
Table 33 North America: Market, By Country, 2017–2024 (USD Million)
Table 34 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 35 North America: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 36 North America: Market, By Cancer Type, 2017–2024 (USD Million)
Table 37 North America: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 38 North America: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 39 North America: Market, By Technology, 2017–2024 (USD Million)
Table 40 North America: Hemato Oncology Testing Market, By End User, 2017–2024 (USD Million)
Table 41 US: Leukemia at A Glance
Table 42 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 43 US: Market, By Cancer Type, 2017–2024 (USD Million)
Table 44 US: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 45 US: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 46 US: Market, By Technology, 2017–2024 (USD Million)
Table 47 US: Market, By End User, 2017–2024 (USD Million)
Table 48 Canada: Hemato Oncology Testing Market, By Product & Service, 2017–2024 (USD Million)
Table 49 Canada: Market, By Cancer Type, 2017–2024 (USD Million)
Table 50 Canada: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 51 Canada: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 52 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 53 Canada: Market, By End User, 2017–2024 (USD Million)
Table 54 Incidence of Leukemia, By Country, 2018–2035
Table 55 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 56 Europe: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 57 Europe: Market, By Cancer Type, 2017–2024 (USD Million)
Table 58 Europe: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 59 Europe: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 60 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 61 Europe: Market, By End User, 2017–2024 (USD Million)
Table 62 Geriatric Population, By Country, 2015 vs 2030
Table 63 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 64 Asia Pacific: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 65 Asia Pacific: Market, By Cancer Type, 2017–2024 (USD Million)
Table 66 Asia Pacific: Hemato Oncology Testing Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 67 Asia Pacific: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 68 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 69 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 70 RoW: Market, By Product & Service, 2017–2024 (USD Million)
Table 71 RoW: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 72 RoW: Market, By Cancer Type, 2017–2024 (USD Million)
Table 73 RoW: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 74 RoW: Hematon Oncology Testing Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 75 RoW: Market, By Technology, 2017–2024 (USD Million)
Table 76 RoW: Market, By End User, 2017–2024 (USD Million)
Table 77 Ranking of Companies in the Market, 2018
List of Figures (29 Figures)
Figure 1 Hemato Oncology Testing Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market: Bottom-Up Approach
Figure 5 Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Hemato Oncology Testing Market, By Product and Service, 2019 vs 2024 (USD Million)
Figure 8 Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Market, By Technology, 2019 vs 2024 (USD Million)
Figure 10 Market, By End User, 2019 vs 2024 (USD Million)
Figure 11 Market, By Region, 2019 vs 2024 (USD Million)
Figure 12 Increasing Incidence of Hematology Cancer to Drive Market Growth
Figure 13 Services to Dominate the North American Market in 2018
Figure 14 North America Accounted for the Largest Market Share in 2018
Figure 15 Hemato Oncology Testing Market: Drivers, Restraints, Opportunities, & Challenges
Figure 16 Market, By Product & Service (2019 vs 2024)
Figure 17 Market, By Cancer Type (2019 vs 2024)
Figure 18 Market, By Technology (2019 vs 2024)
Figure 19 Market, By End User (2019 vs 2024)
Figure 20 Market, By Region (2019 vs 2024)
Figure 21 North America: Hemato Oncology Testing Market Snapshot
Figure 22 Key Developments in the Market From 2016 to 2018
Figure 23 Roche Diagnostic: Company Snapshot (2018)
Figure 24 Abbott Laboratories: Company Snapshot (2018)
Figure 25 Qiagen N.V.: Company Snapshot (2018)
Figure 26 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 27 Illumina, Inc.: Company Snapshot (2018)
Figure 28 Bio-Rad Laboratories, Inc.: Company Snapshot (2018)
Figure 29 Icon PLC: Company Snapshot (2018)
The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as hemato oncology testing product manufacturers, vendors, and distributors; researchers; and research associates and scientists from R&D facilities of pharmaceutical industries were consulted for this report. The demand side of this market is characterized by significant use of hemato oncology testing products due to the increasing prevalence of hematologic cancers. The supply side is characterized by advancements in technology and a shift towards advanced products. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the hemato oncology testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the hemato oncology testing industry.
Report Objectives
- To define, describe, and forecast the hemato oncology testing market by product & service, cancer type, technology, end user, and region
- To forecast the revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
- To identify the micro-markets with respect to drivers, industry-specific challenges, opportunities, and restraints affecting the growth of the market
- To analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players and comprehensively analyze their market ranking and core competencies in terms of market developments and growth strategies
- To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, product launches, and research and development activities in the hemato oncology testing market.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World markets into their respective countries
- Company Information: Detailed analysis and profiling of additional market players (up to 5)
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market
Get in-depth analysis of the COVID-19 impact on the Hemato Oncology Testing Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Hemato Oncology Testing Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Hemato Oncology Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Hemato Oncology Testing Market